- Title
- Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
- Creators
- Christopher LOBO - Florida Cancer Specialists and Research Institute, Gainesville, FL, United StatesGilberto LOPES - The Johns Hopkins Singapore International Medical Centre, Singapore, SingaporePearl SEO - Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, Braman Family Breast Cancer Institute Miller School of Medicine in Miami, The University of Miami, 1475 NW 12 Avenue, SCCC, Suite 3510 (D8-4), Miami, FL 33136, United StatesOrlando SILVA - Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, Braman Family Breast Cancer Institute Miller School of Medicine in Miami, The University of Miami, 1475 NW 12 Avenue, SCCC, Suite 3510 (D8-4), Miami, FL 33136, United StatesJoyce SLINGERLAND - Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, Braman Family Breast Cancer Institute Miller School of Medicine in Miami, The University of Miami, 1475 NW 12 Avenue, SCCC, Suite 3510 (D8-4), Miami, FL 33136, United StatesKeleni TUKIA - Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, Braman Family Breast Cancer Institute Miller School of Medicine in Miami, The University of Miami, 1475 NW 12 Avenue, SCCC, Suite 3510 (D8-4), Miami, FL 33136, United StatesCatherine WELSH - Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, Braman Family Breast Cancer Institute Miller School of Medicine in Miami, The University of Miami, 1475 NW 12 Avenue, SCCC, Suite 3510 (D8-4), Miami, FL 33136, United StatesStefan GLÜCK - Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, Braman Family Breast Cancer Institute Miller School of Medicine in Miami, The University of Miami, 1475 NW 12 Avenue, SCCC, Suite 3510 (D8-4), Miami, FL 33136, United StatesOdalys BAEZ - Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, Braman Family Breast Cancer Institute Miller School of Medicine in Miami, The University of Miami, 1475 NW 12 Avenue, SCCC, Suite 3510 (D8-4), Miami, FL 33136, United StatesAurelio CASTRELLON - Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, Braman Family Breast Cancer Institute Miller School of Medicine in Miami, The University of Miami, 1475 NW 12 Avenue, SCCC, Suite 3510 (D8-4), Miami, FL 33136, United StatesAnnapoorna FERRELL - Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, Braman Family Breast Cancer Institute Miller School of Medicine in Miami, The University of Miami, 1475 NW 12 Avenue, SCCC, Suite 3510 (D8-4), Miami, FL 33136, United StatesConnie HIGGINS - Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, Braman Family Breast Cancer Institute Miller School of Medicine in Miami, The University of Miami, 1475 NW 12 Avenue, SCCC, Suite 3510 (D8-4), Miami, FL 33136, United StatesErin HURLEY - Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, Braman Family Breast Cancer Institute Miller School of Medicine in Miami, The University of Miami, 1475 NW 12 Avenue, SCCC, Suite 3510 (D8-4), Miami, FL 33136, United StatesJudith HURLEY - Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, Braman Family Breast Cancer Institute Miller School of Medicine in Miami, The University of Miami, 1475 NW 12 Avenue, SCCC, Suite 3510 (D8-4), Miami, FL 33136, United StatesIsildinha REIS - Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, Braman Family Breast Cancer Institute Miller School of Medicine in Miami, The University of Miami, 1475 NW 12 Avenue, SCCC, Suite 3510 (D8-4), Miami, FL 33136, United StatesStephen RICHMAN - Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, Braman Family Breast Cancer Institute Miller School of Medicine in Miami, The University of Miami, 1475 NW 12 Avenue, SCCC, Suite 3510 (D8-4), Miami, FL 33136, United States
- Publication Details
- Breast cancer research and treatment, Vol.123(2), pp.427-435
- Publisher
- Springer; Dordrecht
- Academic Unit
- Miller School of Medicine; UMMG Department of Public Health Sciences Research; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- PMID
- 20585851
- Record Identifier
- 991031562019602976
Journal article
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
Breast cancer research and treatment, Vol.123(2), pp.427-435
2010
PMID: 20585851
Metrics
13 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.119 Breast Cancer Scanning
- 1.119.259 HER2
- Web Of Science research areas
- Oncology
- ESI research areas
- Clinical Medicine
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites